<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104369">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02124161</url>
  </required_header>
  <id_info>
    <org_study_id>B1851138</org_study_id>
    <nct_id>NCT02124161</nct_id>
  </id_info>
  <brief_title>Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.</brief_title>
  <official_title>A Phase 4, Randomized, Double-blind Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine in Adults 50 Years and Older Who Received 1 Or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine Prior to Study Enrollment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety of 13-valent
      pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated
      influenza vaccine to adults 50 years and older who have previously received 23-valent
      pneumococcal polysaccharide vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>The pneumococcal serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs)</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The hemagglutination inhibition (HAI) geometric mean titers (GMTs) for each influenza virus strain in the SIIV</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The number and proportion of subjects with adverse events (AEs) and serious adverse events (SAEs).</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieving pneumococcal serotype-specific OPA titers greater than or equal to the lower limit of quantitation (LLOQ).</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pneumococcal serotype-specific OPA geometric mean fold rises (GMFRs).</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving seroconversion in HAI titers.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The HAI GMFRs for each influenza virus strain.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">882</enrollment>
  <condition>PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE</condition>
  <arm_group>
    <arm_group_label>13vPnC+SIIV/Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+SIIV/13vPnC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.</description>
    <arm_group_label>13vPnC+SIIV/Placebo</arm_group_label>
    <other_name>13vPnC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal Inactivated Influenza Vaccine</intervention_name>
    <description>One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.</description>
    <arm_group_label>13vPnC+SIIV/Placebo</arm_group_label>
    <other_name>SIIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.</description>
    <arm_group_label>13vPnC+SIIV/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.</description>
    <arm_group_label>Placebo+SIIV/13vPnC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal Inactivated Influenza Vaccine</intervention_name>
    <description>One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.</description>
    <arm_group_label>Placebo+SIIV/13vPnC</arm_group_label>
    <other_name>SIIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.</description>
    <arm_group_label>Placebo+SIIV/13vPnC</arm_group_label>
    <other_name>13vPnC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Evidence of a personally signed and dated informed consent document (ICD) indicating
             that the subject has been informed of all pertinent aspects of the study.

          2. Male or female adults 50 years of age or older.

          3. Documented vaccination with 1 or more prior doses of 23vPS, the last given at least 1
             year prior to study enrollment.

          4. Negative urine pregnancy test for all female subjects who are of child bearing
             potential.

        Exclusion Criteria:

          1. Previous vaccination with Prevnar®, Prevnar 13®, or any other investigational
             pneumococcal conjugate vaccine.

          2. History of severe adverse reactions associated with any vaccine or vaccine-related
             component.

          3. Allergic to egg proteins (egg or egg products) and chicken proteins.

          4. History of Guillain-Barré syndrome.

          5. Vaccination with any influenza vaccine within 6 months (182 days) before
             investigational product administration.

          6. Documented S pneumoniae infection within the past 5 years before investigational
             product administration.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851138&amp;StudyName=Concomitant%20administration%20of%2013-valent%20Pneumococcal%20Conjugate%20Vaccine%20%2813vPnC%29%20with%20influenza%20vaccine%20in%2023-valent%20Pneumococcal%20Polysaccharid</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal polysaccharide vaccine</keyword>
  <keyword>13-valent pneumococcal conjugate vaccine</keyword>
  <keyword>invasive pneumococcal disease</keyword>
  <keyword>flu vaccine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
